Identification of Five Immune Subtypes in Tongue Cancer for Personalized Therapy
New research identifies five immune microenvironment subtypes in tongue squamous cell carcinoma, providing a pathway to personalized immunotherapy and improved treatment outcomes.
Recent research has unveiled five distinct immunotypes in tongue squamous cell carcinoma (TSCC), a prevalent form of oral cancer. This breakthrough, led by Professor Miyuki Azuma from the Institute of Science Tokyo, utilized advanced immune profiling techniques, including multiplex immunofluorescence and spatial tissue analysis, to map the immune landscape within tumors.
The study identified that not all TSCC tumors respond equally to immunotherapy, primarily due to their immune microenvironment. The five immunotypes include:
- Immunoactive Type I: Characterized by active immune cells capable of responding well to current immune checkpoint inhibitors (ICIs). However, this type is rare, comprising only a small percentage of cases.
- Immunosuppressed Type III: Exhibits active suppression of immune responses, making immunotherapy less effective.
- Immunoisolating Type IV: Contains immune cells that are unable to effectively engage with cancer cells, leading to immune evasion.
- Immunodepleted or 'immune desert' Type V: Shows minimal immune cell infiltration, indicating a non-inflamed tumor microenvironment.
Most TSCC cases (approximately 70%) fall into types III–V, which explains the limited success of current immunotherapies, such as PD-1/PD-L1 inhibitors, in treating this cancer. Importantly, traditional cancer staging systems do not effectively predict these immune profiles, emphasizing the need for immune-based diagnostics.
The findings suggest that personalized treatment strategies could significantly improve outcomes. Patients with immunoactive tumors may benefit from ICIs alone, while those with immunosuppressive or isolated microenvironments might require combination therapies or novel approaches to overcome immune resistance. This classification system paves the way for more targeted and effective intervention, moving toward precision oncology for TSCC.
Overall, this research marks a critical step forward in tailoring immunotherapy for tongue cancer, potentially leading to higher response rates and better patient prognoses.
Source: https://medicalxpress.com/news/2025-05-immune-tongue-cancer-personalized-treatment.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Targeting Astrocytic GABA Production to Promote Spinal Cord Repair and Neuronal Regeneration
A groundbreaking study reveals that inhibiting GABA production in astrocytes can promote spinal cord repair and neuronal regeneration, offering new hope for injury recovery. Researchers identify the MAOB enzyme as a key target, with promising results in animal models and safety validated in clinical trials.
How Short Bowel Syndrome Treatments Induce Cellular Changes in the Intestine: Insights from a Longitudinal Study
A groundbreaking longitudinal study reveals how GLP-2 analog therapy induces cellular remodeling in the intestine, improving nutrient absorption and reducing inflammation in short bowel syndrome patients.
Clinical Data Challenges CMS's Proposed 'Efficiency Adjustment' in Medicare Payments
Recent research challenges CMS's proposal to cut Medicare physician payments by 2.5%, showing surgical times have not decreased. The study calls for evidence-based policy decisions to ensure fair compensation aligned with current clinical practice.
Emerging Off-Label Use of Leucovorin Shows Promise in Helping Children with Autism Speak
Emerging research suggests that the off-label use of leucovorin, a low-cost drug, may significantly improve speech in children with autism, highlighting the need for further studies and FDA approval.